XML 46 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Segments (Tables)
12 Months Ended
Dec. 31, 2024
Segments  
Schedule of segment net loss by significant expense category

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

    

2024

    

2023

    

​

2022

Compensation and benefits, excluding stock-based compensation

​

$

7,438

 

$

6,737

 

$

7,239

Stock-based compensation

​

​

3,003

 

​

2,148

 

​

2,691

Drug manufacturing

​

​

2,485

 

​

2,195

 

​

11,213

Clinical trial

​

​

4,148

 

​

2,716

 

​

3,159

Outside general and administrative

​

​

3,101

 

​

2,703

 

​

2,978

Facilities and insurance

​

​

3,219

 

​

3,160

 

​

3,342

Other segment items (1)

​

​

4,154

 

​

3,748

 

​

1,943

Total segment expense

​

​

27,548

 

​

23,407

 

​

32,565

Non-operating income and expense, net

​

​

34,745

 

​

3,622

 

​

8,742

Net loss

​

$

62,293

 

$

27,029

 

$

41,307

​

(1)Includes consulting, non-clinical research and laboratory supplies.